Compare Calistoga Pharmaceuticals vs Neuraltus Pharmaceuticals
Customers evaluate the quality of Calistoga Pharmaceuticals's products using the following success metrics.
Overview
Calistoga Pharmaceuticals is 18 yrs old and is based in United States.
Calistoga Pharmaceuticals is a biopharmaceutical company developing multiple compounds selectively targeting the PI3K pathway, a pathway known to be involved in certain cancers and inflammatory diseases. In February 2011, Calistoga Pharmaceuticals was acquired by Gilead Sciences. The valuation of Calistoga Pharmaceuticals was $375 million.
Neuraltus Pharmaceuticals is based in United States
Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.
Demo Video
Leadership
Neill Giese (Chief Security Officer)
Richard L Casey (Chief Executive Officer)
Funding
Investors
Gilead Sciences, Frazier Healthcare Partners
Latterell Venture Partners, VantagePoint Capital Partners
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Calistoga Pharmaceuticals has not claimed their profile.
Work for Calistoga Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Calistoga Pharmaceuticals?
Claim your profile now.
Information not available because Neuraltus Pharmaceuticals has not claimed their profile.
Work for Neuraltus Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Neuraltus Pharmaceuticals?
Claim your profile now.